AbbottLaunchesNavitor™, its Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosisin
News Editor, Takmaa News, Kolkata, 10th Dec 2022 : Global healthcare company, Abbott today announced that it has launchedits latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, makingthe minimally invasive device availablefor people in India withsevereaortic stenosis who are at high or extreme surgical risk.With the Navitor valve, the company is advancing TAVI (also referred to as TAVR, or transcatheter aortic valve replacement) therapies with innovations including a unique design to prevent blood leaking around the valve.The Navitor TAVI system is the latest addition to the company’scomprehensivestructural heart transcatheter portfolio thatoffers physicians and patients less invasive optionsto treatheart diseases.
Aortic stenosis is one of the most common and life-threatening heart valve diseases. It restricts blood flow through the aortic heart valve to the rest of the body, which can lead to heart failure and, in certain cases, sudden cardiac death.[i]While many people don’t have noticeable symptoms, in India, one in 40 people aged 75 and older have severe, symptomatic aortic stenosis.[ii]For these people, open-heart surgery is considered a high-risk procedure due to the potential complications stemming from age, frailty or having multiple other diseases or conditions.[iii] TAVI serves as a less invasive alternative to surgical aortic valve replacement and can reduce symptoms and improve the lives of patients with this debilitating condition.
Prior to TAVI, the standard of care for severe aortic stenosis was surgical aortic valve replacement, but not all patients were candidates for open-heart surgery.
“For people in India suffering from aortic stenosis and unable to have surgery, this TAVI system offers a safe and effective treatment option. The size ranges allow for patient-specific sizing and optimal valve function,” said Dr. Ashok Seth, Chairman Fortis Escorts Heart Institute and Chairman Fortis Medical Council, New Delhi. “While transcatheter valve replacement has for some time been a standard of care for elderlypatients with a narrowing of the aortic valve, this device helps to address challenges we sometimes find in current TAVI systems when we encounter challenging patient anatomies which may lead to potential problems and difficulties.”
Navitor features a unique fabric cuff (NaviSeal™)thatworks with the cardiac cycle to reduce or eliminate a backflow of blood around the valve frame known as paravalvular leak (PVL), a common complication following TAVI procedures. The new device is the only self-expanding TAVI system with intra-annular (within the native valve) leafletsand large frame cells–features designed to help improve access to critical coronary arteries to facilitate future interventions to treat coronary artery disease (CAD). The new design additionallyprovidesimproved hemodynamics, or better blood flow.
The Navitor device is implanted with Abbott’s FlexNavdelivery system, whichoffers a slim design with the lowest TAVI delivery system profile, allowingtreatment of peoplewith vessels as small as 5.0 mm. The slim catheter can accommodate different aorticanatomies for stable, predictable and accurate valve delivery and placement.
“The innovative design of the Navitor valve paired with the FlexNav delivery system streamlines and simplifiesTAVI procedures for physicians and helps with better valve placement and performance for patients, giving them a more robust set of solutions to treat this condition,” said Payal Agrawal, General Manager, Emerging Asia and Korea, Abbott. “This latest and important product represents another milestone in Abbott’s mission to provide the most comprehensive treatment options to address cardiovascular conditions and improve quality of life so people can get back to doing the things they love,” she added.
